Actively Recruiting
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Led by The First Affiliated Hospital of Soochow University · Updated on 2026-05-01
31
Participants Needed
1
Research Sites
336 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Aim of this study will evaluate the Efficacy and Safety of Anti-PD-1 monoclonal antibody Combined Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
CONDITIONS
Official Title
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed relapsed or refractory Peripheral T-cell Lymphoma with measurable lesions larger than 1.5 cm
- Disease status includes less than 50% reduction after prior treatments, progression after first-line therapy, or new/increased lesions after stem cell transplant
- Age 18 years or older
- ECOG performance status of 2 or less
- Adequate organ function including specific blood counts, heart function (LVEF ≥50%), liver enzymes, kidney function (CR or CCr ≥60 ml/min), lung function (Level 1 or less), no significant dyspnea, and oxygen saturation above 91%
- Willingness to use birth control during the study and for one year after
- Estimated survival of at least 3 months
- Voluntary signing of informed consent
You will not qualify if you...
- Major surgery within 4 weeks before starting treatment
- Previous other malignancies except cured tumors without active lesions for 3 years or certain treated skin and tonsil cancers
- Failed previous allogeneic hematopoietic stem cell transplantation
- Stroke or brain hemorrhage within the last 3 months
- Serious heart disease (NYHA class 3 or 4), recent heart attack within 6 months, uncontrolled arrhythmias, or serious lung disease
- HIV infection or active hepatitis B or C
- Uncontrolled systemic infections
- Pregnancy or breastfeeding
- Any life-threatening disease or organ dysfunction that may risk safety or interfere with treatment absorption or study results as judged by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000
Actively Recruiting
Research Team
C
Caixia Li, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here